FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214293855> ?p ?o ?g. }

• W3214293855 endingPage "A795" @default.
• W3214293855 startingPage "A795" @default.
• W3214293855 abstract "Background While STING-activating agents have shown limited efficacy in early phase clinical trials, multiple lines of evidence suggest the importance of the so far unappreciated tumor cell-intrinsic STING function in antitumor immune responses. Accordingly, we have shown that although there is a widespread impairment of STING signaling among human melanomas, its restoration through epigenetic reprogramming can augment antigenicity and T cell recognition of melanoma cells. 1 2 In this study, we determined if rescue of tumor cell-intrinsic STING signaling using a DNA methyltransferase inhibitor can improve the therapeutic efficacy of a STING agonist in mouse models of melanoma. Methods We subjected three distinct murine melanoma cell lines (B16-F10, B16-ISG and Yumm1.7) to treatment with 5-aza-2'-deoxycytidine (5AZADC) and evaluated their activation of STING following stimulation with the STING agonist ADU-S100. Using a B16-F10 subcutaneous model, we assessed the effect of 5AZADC treatment on the efficacy of intratumorally administered ADU-S100 in STINGgt/gt mice. Additionally, we performed mechanistic studies using T-cell depletion experiments as well as phenotypic and gene expression profiling. Results We observed reconstitution of cGAS in all three 5AZADC-pretreated cell lines as well as up to a 46-fold increase in induction of IFN-beta (p < 0.001) and a 4.5-fold increase in MHC class I surface expression (p < 0.01) compared to untreated controls following stimulation with ADU-S100. In B16-F10 tumor-bearing mice, while treatment with a combination of 5AZADC plus ADU-S100 resulted in a marked increase in Ifnb1 transcripts within tumors (p < 0.001), it significantly delayed tumor growth compared to treatment with ADU-S100 alone (p = 0.0244 on day 22). Antibody-mediated depletion studies in mice receiving the combination therapy further indicated that this antitumor activity depends on the generation of functional tumor antigen-specific CD8+ T cells (p = 0.0111 on day 22); however, tumor growth remained unaltered by the depletion of CD4+ T cells. Conclusions We show that reversal of methylation silencing of cGAS in murine melanoma cell lines using a clinically available DNA methylation inhibitor can improve agonist-induced STING activation and type I IFN induction, which in tumor-bearing mice is capable of inducing tumor regression through a CD8+ T cell-dependent immune response. These findings not only provide mechanistic insight into how STING signaling dysfunction in tumor cells can contribute to impaired responses to STING agonist therapy, but also suggest, depending on tumor cell-intrinsic STING signaling status, its pharmacologic restoration should be considered for improving therapeutic efficacy of STING agonists in future clinical studies. Acknowledgements Funding: NCI P50 CA168536, Cindy and Jon Gruden Fund, Chris Sullivan Fund, V Foundation, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. References Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ. STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity. Cancer Immunol Res 2019; 7 (11):1837–48. Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic reprogramming of tumor cell–intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. PNAS 2021; 118 (15)." @default.
• W3214293855 created "2021-11-22" @default.
• W3214293855 creator A5004554374 @default.
• W3214293855 creator A5006278901 @default.
• W3214293855 creator A5035616597 @default.
• W3214293855 creator A5050436106 @default.
• W3214293855 creator A5057006257 @default.
• W3214293855 creator A5082896599 @default.
• W3214293855 date "2021-11-01" @default.
• W3214293855 modified "2023-09-25" @default.
• W3214293855 title "760 In vivo demethylation-mediated reversal of tumor cell-intrinsic cGAS silencing improves the efficacy of STING agonist therapy" @default.
• W3214293855 doi "https://doi.org/10.1136/jitc-2021-sitc2021.760" @default.
• W3214293855 hasPublicationYear "2021" @default.
• W3214293855 type Work @default.
• W3214293855 sameAs 3214293855 @default.
• W3214293855 citedByCount "0" @default.
• W3214293855 crossrefType "journal-article" @default.
• W3214293855 hasAuthorship W3214293855A5004554374 @default.
• W3214293855 hasAuthorship W3214293855A5006278901 @default.
• W3214293855 hasAuthorship W3214293855A5035616597 @default.
• W3214293855 hasAuthorship W3214293855A5050436106 @default.
• W3214293855 hasAuthorship W3214293855A5057006257 @default.
• W3214293855 hasAuthorship W3214293855A5082896599 @default.
• W3214293855 hasBestOaLocation W32142938551 @default.
• W3214293855 hasConcept C126322002 @default.
• W3214293855 hasConcept C127413603 @default.
• W3214293855 hasConcept C136449434 @default.
• W3214293855 hasConcept C146978453 @default.
• W3214293855 hasConcept C150903083 @default.
• W3214293855 hasConcept C170493617 @default.
• W3214293855 hasConcept C203014093 @default.
• W3214293855 hasConcept C207001950 @default.
• W3214293855 hasConcept C2776090121 @default.
• W3214293855 hasConcept C2777349159 @default.
• W3214293855 hasConcept C2777658100 @default.
• W3214293855 hasConcept C2778938600 @default.
• W3214293855 hasConcept C2779300339 @default.
• W3214293855 hasConcept C502942594 @default.
• W3214293855 hasConcept C71924100 @default.
• W3214293855 hasConcept C86803240 @default.
• W3214293855 hasConcept C8891405 @default.
• W3214293855 hasConcept C98274493 @default.
• W3214293855 hasConceptScore W3214293855C126322002 @default.
• W3214293855 hasConceptScore W3214293855C127413603 @default.
• W3214293855 hasConceptScore W3214293855C136449434 @default.
• W3214293855 hasConceptScore W3214293855C146978453 @default.
• W3214293855 hasConceptScore W3214293855C150903083 @default.
• W3214293855 hasConceptScore W3214293855C170493617 @default.
• W3214293855 hasConceptScore W3214293855C203014093 @default.
• W3214293855 hasConceptScore W3214293855C207001950 @default.
• W3214293855 hasConceptScore W3214293855C2776090121 @default.
• W3214293855 hasConceptScore W3214293855C2777349159 @default.
• W3214293855 hasConceptScore W3214293855C2777658100 @default.
• W3214293855 hasConceptScore W3214293855C2778938600 @default.
• W3214293855 hasConceptScore W3214293855C2779300339 @default.
• W3214293855 hasConceptScore W3214293855C502942594 @default.
• W3214293855 hasConceptScore W3214293855C71924100 @default.
• W3214293855 hasConceptScore W3214293855C86803240 @default.
• W3214293855 hasConceptScore W3214293855C8891405 @default.
• W3214293855 hasConceptScore W3214293855C98274493 @default.
• W3214293855 hasIssue "Suppl 3" @default.
• W3214293855 hasLocation W32142938551 @default.
• W3214293855 hasLocation W32142938552 @default.
• W3214293855 hasOpenAccess W3214293855 @default.
• W3214293855 hasPrimaryLocation W32142938551 @default.
• W3214293855 hasRelatedWork W2016263096 @default.
• W3214293855 hasRelatedWork W2900220188 @default.
• W3214293855 hasRelatedWork W2921466126 @default.
• W3214293855 hasRelatedWork W3102023043 @default.
• W3214293855 hasRelatedWork W3128071834 @default.
• W3214293855 hasRelatedWork W3183549888 @default.
• W3214293855 hasRelatedWork W3203953717 @default.
• W3214293855 hasRelatedWork W4220660635 @default.
• W3214293855 hasRelatedWork W4319230671 @default.
• W3214293855 hasRelatedWork W4324122282 @default.
• W3214293855 hasVolume "9" @default.
• W3214293855 isParatext "false" @default.
• W3214293855 isRetracted "false" @default.
• W3214293855 magId "3214293855" @default.
• W3214293855 workType "article" @default.